A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations by Felderbauer, Peter et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Gastroenterology
Open Access Research article
A novel mutation of the calcium sensing receptor gene is associated 
with chronic pancreatitis in a family with heterozygous SPINK1 
mutations
Peter Felderbauer*, Peter Hoffmann, Henrik Einwächter, Kerem Bulut, 
Nikolaus Ansorge, Frank Schmitz and Wolfgang E Schmidt
Address: Laboratory for Experimental Gastroenterology, Department of Internal Medicine I, St. Josef-Hospital, Ruhr-University of Bochum
Email: Peter Felderbauer* - peter.felderbauer@rub.de; Peter Hoffmann - ced-ambulanz@elis-stiftung.de; 
Henrik Einwächter - henrik.einwaechter@rub.de; Kerem Bulut - kbulut@web.de; Nikolaus Ansorge - n.ansorge@gmx.de; 
Frank Schmitz - frank.schmitz@rub.de; Wolfgang E Schmidt - wolfgang.e.schmidt@rub.de
* Corresponding author    
chronic pancreatitisidiopathic chronic pancreatitisSPINK1 mutationcalcium sensing receptor
Abstract
Background: The role of mutations in the serine protease inhibitor Kazal type 1 (SPINK1) gene
in chronic pancreatitis is still a matter of debate. Active SPINK1 is thought to antagonize activated
trypsin. Cases of SPINK1 mutations, especially N34S, have been reported in a subset of patients
with idiopathic chronic pancreatitis. However, the inheritance pattern is still unknown. Some cases
with N34S heterozygosity have been reported with and without evidence for CP indicating neither
an autosomal recessive nor dominant trait. Therefore SPINK1 mutations have been postulated to
act as a disease modifier requiring additional mutations in a more complex genetic model. Familial
hypocalciuric hypercalcemia (FHH) caused by heterozygous inactivating mutations in the calcium
sensing receptor (CASR) gene is considered a benign disorder with elevated plasma calcium levels.
Although hypercalcemia represents a risk factor for pancreatitis, increased rates of pancreatitis in
patients with FHH have not been reported thus far.
Methods: We studied a family with a FHH-related hypercalcemia and chronic pancreatitis. DNA
samples were analysed for mutations within the cationic trypsinogen (N29I, R122H) and SPINK1
(N34S) gene using melting curve analysis. Mutations within CASR gene were identified by DNA
sequencing.
Results: A N34S SPINK1 mutation was found in all screened family members. However, only two
family members developed chronic pancreatitis. These patients also had FHH caused by a novel,
sporadic mutation in the CASR gene (518T>C) leading to an amino acid exchange (leucine->proline)
in the extracellular domain of the CASR protein.
Conclusion: Mutations in the calcium sensing receptor gene might represent a novel as yet
unidentified predisposing factor which may lead to an increased susceptibility for chronic
pancreatitis. Moreover, this family analysis supports the hypothesis that SPINK1 mutations act as
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disease modifier and suggests an even more complex genetic model in SPINK1 related chronic
pancreatitis.
Background
Chronic pancreatitis (CP) remains one of the big chal-
lenges among the GI-tract disorders. Since 1996 the
understanding of genetic risk factors for CP extended with
the discovery of different gene defects causing hereditary
pancreatitis (HP). A French and two American groups
were the first to identify chromosome 7q35 as a putative
locus for HP [1-3]. The disease gene was mapped and a
heterozygous point mutation A>T in exon 3 (R122H) of
the protease serine 1 (PRSS1) was detected in a majority
(~70%) of cases with cationic trypsinogen mutations [4].
Subsequently the PRSS1  mutations N29I (25%), A16V
(<3%), K23R, D22G, R122C and N29T (several kindreds)
were discovered [4-9]. The second gene that was character-
ized to be clearly associated with idiopathic chronic pan-
creatitis (ICP) was the cystic fibrosis transmembrane
conductance regulator (CFTR) gene [10,11].
The third gene that was postulated to be associated with
ICP is the serine protease inhibitor Kazal type 1 (SPINK1).
Initially an autosomal recessive inheritance pattern was
suspected for the N34S SPINK1 mutation resulting in CP
in homozygous patients while another heterozygous sub-
group seems to suffer from disease due to a combination
of genetic defects of SPINK1 and yet unidentified genes
[12]. Pfützer et al. showed that neither an autosomal
dominant disorder with a low penetrance pattern
(observed frequency of N34S mutation in the population
[0.77%] versus ICP prevalence [0.0066%]) nor an auto-
somal recessive trait can be used as a model for disease
inheritance [13]. The prevalence for the N34S mutation in
tested healthy controls stemming from these countries
ranges in between 1.6 % (USA) [13], 1.58% (France) [14]
and 0.36% (Germany) [12]. Thus the role of SPINK1
mutations in ICP which have a much lower disease prev-
alence (<0.01%) remains to be further defined and the
hypothesis of a modifying but not causative factor for
SPINK1 mutations was proposed [13,15].
One of the toxic metabolic risk factors for CP is hypercal-
cemia. The correlation was first observed in patients with
hyperparathyroidism while trypsin activation, secretion
stimulus and stabilization are suspected mechanisms
[16].
Therefore, mutations in genes involved in calcium home-
ostasis might be associated with an increased risk for CP.
We describe a family with members suffering from both
CP and familial hypocalciuric hypercalcemia (FHH) to
investigate the association of calcium sensing receptor
gene (CASR) and SPINK1 mutations with CP.
Case Presentation
We report on a 35-year-old caucasian male (II:4, Fig. 3)
who was admitted to the hospital with an acute exacerba-
tion of chronic pancreatitis in 2002. In 1993, he had been
hospitalized for a first episode of acute pancreatitis that
was followed by 40 recurrent exacerbations necessitating
27 periods of prolonged hospitalization. While the aetiol-
ogy of pancreatitis remained undefined between 1993
and 1996, prolonged hypercalcemia in combination with
an elevated level of parathormone (PTH) were suspected
as the dominating causes in 1996.
A familial hypocalciuric hypercalcemia (FHH) was diag-
nosed biochemically by measuring a persisting high
serum calcium level and a low urinary calcium excretion.
The ratio of the creatinine and calcium clearance was
below 0.01. The fact that his older brother (II:2, Fig. 3)
had the same complex of symptoms (recurrent pancreati-
tis, elevated serum calcium level and low urinary calcium
excretion) supported the hypothesis of a genetic cause and
the diagnosis of FHH. In the younger brother, the disease
onset occurred at the age of 27 years. In the patient, treat-
ment with bisphosphonates and octreotide (200 µg TID)
was initiated in 1995 and continued through 2001 with
little to none clinical improvement.
In 1996, the two lower parathyroid glands were removed
surgically because of persistent elevated PTH serum levels
and calcitonin substitution was started (100 µg BID). This
therapy also failed to suppress the recurrent episodes of
pancreatitis.
In December 1999, the patient was the first time admitted
to our clinic with another exacerbation of his recurrent
pancreatitis. After endoscopic investigation (ERCP and
endoscopic ultrasound), indicating neither signs of
chronic pancreatitis nor any evidence for the pathology of
his disease, we suspected that additive genetic alterations
might cause the disease. An analysis for PRSS1 mutations
was performed which revealed neither an R122H or N29I
mutation.
In 2001, during another episode of acute pancreatitis,
clinical evaluation revealed marked signs of chronic pan-
creatitis according to the Marseilles-Rome criteria. The
endoscopic ultrasound was consistent with chronic calci-
fying pancreatitis with intraductal stones within the headBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/34
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of the pancreas. Persistent pain and impaired exocrine
function with an abnormal fecal elastase accompanied the
disease progress. A heterozygous N34S mutation was
detected by DNA sequence analysis of the SPINK1 gene.
Blood samples and DNA studies
We collected blood samples for clinical chemistry and 24
h urine of all family members who accepted testing. Blood
samples for mutation analysis were taken after counsel-
ling according to the guidelines of the Consensus Com-
mittees of the European Registry of Hereditary Pancreatic
Diseases [17].
Informed consent was given by the patient's mother (62),
the elderly brother (43), while a half-sister of the index
patient (24) denied genetic testing. The daughter (8) of
the index patient was tested giving her and her parents
informed consent. We extracted genomic DNA from
whole blood according to established protocols.
Coded DNA samples of the patients were analyzed for
PRSS1 mutations (N29I, R122H) and the SPINK1 variant
N34S by melting point curve analysis. DNA sequencing of
the CASR gene were performed using PCR products of the
exons.
Polymerase Chain Reaction and melting point curve 
analysis
Primers flanking the designated coding regions of the
CASR, PRSS1 and SPINK1 genes were designed according
to the nucleotide sequences published (CASR: GenBank
#U20759 [18], PRSS1: GenBank #U66061 [19] and
SPINK1: GenBank #AF286028 [12]).
Melting curve analyses for the N29I, R122H PRSS1 muta-
tions were performed using specific pairs of fluorescence
resonance energy transfer (FRET) probes (N29I: LC-Red
attached to 5'-CTGTCCCCTACCAGGTGTCC and FL
attached to 5'-GGGCTACAACTGTGAG GAGAA-FL ;
R122H: LC-Red 5'-TCTCTGCCCACCGCCCCTCCAGCC
and 5'-CAACGCCCACGTGTCCACCA-FL) synthesized by
TIB MOLBIOL (Berlin, Germany) and the LightCycler
(Roche Diagnostics, Germany). Primers for the SPINK1
melting curve analysis have been described previously
[12].
DNA sequence analysis
Genomic DNA was prepared from whole blood using
standardized protocols. The patient was screened for pub-
lished mutations in the 6 translated exons (exon 2–7) of
the CASR gene. PCR products of all 6 exons were gel-puri-
fied and sequenced on an ABI PRISM 377 DNA sequencer
(Applied Biosystems, Foster, CA) using the listed primers
(Table 1). DNA from relatives of the patient was screened
for mutations in exon 4 identified in the index patient's
DNA c.518T>C.
Results
Family history
The family history revealed no other family members with
pancreatitis, with the exception of the two previously
mentioned brothers (36 and 39 years), who both experi-
enced a first episode at the age of 27. The father had died
of cardiac arrest in 1971 and never had any documented
illness or symptoms indicating pancreatitis. The daughter
of the index patient is asymptomatic but still at risk to
develop pancreatitis. The brother who had a documented
history of recurrent pancreatitis and FHH could not be
located. Looking at the family tree and his medical history
of recurrent episodes of pancreatitis, a N34S mutation can
only be suspected.
Clinical chemistry
Serum plasma levels of Ca2+, creatinine and urinary cal-
cium excretion were normal in the mother and asympto-
matic brother. The ratio of creatinine clearance and
calcium clearance was within normal limits and thus not
indicating FHH. The index patient (12/2001) had a nor-
mal PTH serum concentration of 19.0 ng/l (normal 12–72
ng/l) and an elevated plasma calcium between 2.75 and
3.25 mmol/l. Urinary calcium excretion was 180 mg/24 h,
creatinine clearance was 164 ml/min and the ratio of cre-
atinine and calcium clearance was 0.014.
Polymerase Chain Reaction, melting point curve analysis 
and DNA sequencing
The data of the melting point curve analysis revealed a
heterozygous N34S mutations for the index patient, the
unaffected brother, mother and daughter (Figure 1).
The sequence similarity search of the CASR gene showed
a point mutation in exon 4 at position c.518T>C leading
to a heterozygous missense mutation L173P in the extra-
cellular domain of the calcium sensing receptor (CaR)
protein in the index patient and his daughter (Figure 1
and 2).
The other family members who had no clinical signs for
FHH (normal plasma and urinary Ca2+ excretion; Tab.2)
did not have a CASR gene mutation in exon 4. The results
of the mutational analysis are summarized in the family
tree (Fig. 3).
Discussion
Hypercalcemia is considered a risk factor of acute pancre-
atitis. Elevated serum calcium levels can lead to premature
activation of trypsinogen inducing autodigestion of the
pancreatic parenchyma [20]. Clinical examples for this
association are patients with endocrine disorders such asBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/34
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primary hyperparathyroidism (pHPT) characterized by
hypercalcemia with an elevated risk for pancreatitis. How-
ever, this interrelation is questioned by some investigators
and for the specific case of pancreatitis in patients with
primary hyperparathyroidism the prevalence rates range
from 1 to 19 % [21]. In our case, FHH-associated hyper-
calcemia was thought to be required for recurrent epi-
sodes of acute pancreatitis but even parathyroidectomy
and treatment with bisphosphonates did not bring the
expected result. FHH is a benign disorder with a slight ele-
vation of plasma Ca2+. It is inherited in an autosomal
dominant order and shows almost 100% penetrance. In
1992, the disease gene (CASR) was mapped to the long
arm of chromosome 3 [22] and today more than 70 muta-
tions have been described [23]. The CaR plays a key role
in calcium homeostasis and is widely expressed in tissues
including kidney, parathyroid glands and bone cells
which are involved in calcium metabolism [24]. Recently
the CaR was characterized in human pancreatic acinar and
duct cells [25]. However, the functional significance of
CaR expression in pancreatic acinar and duct cells in the
pathogenesis of pancreatitis remains to be defined.
While a heterozygous inactivating CASR mutation leads
to FHH, homozygous mutations result in severe neonatal
pHPT. In contrast to pHPT, pancreatitis is an unusual
complication of FHH.
Melting curve analysis (SPINK1 N34S) of the index patient and family members Figure 1
Melting curve analysis (SPINK1 N34S) of the index patient and family members To assess the SPINK1 genotype, 
representative gene fragments of the SPINK1 gene were amplified by PCR. The melting point (Tm) of each amplified double-
stranded DNA fragment was determined using the LightCycler thermocycling device and designated probes. Curves with a 
melting point at 58,53°C represent the SPINK1 (N34S) control, index patient (II:4), daughter of the index patient (III:1), healthy 
brother (II:3) and healthy mother of the index patient (I:2). The melting point curve with the higher melting point at 63,17°C, 
due to a more stable complex (donor probe was complimentary to the wild type) represents the SPINK1 wild type.
Tm 63 ,17°C 
Tm 58,53°C
SPINK1 wild type
I:2
II:3
II:4
N34S 
homozygous
control
III:1BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/34
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Interestingly, there are a few reports of as yet unexplained
cases with FHH and recurrent episodes of pancreatitis
[26,27]. Pearce et al. (1996) suspected in their collective
of three FHH kindreds [26] that patients with FHH and
CP may represent a distinct subgroup. Subsequently they
identified three different CASR mutations, suggesting that
they may represent distinct FHH variants with pancreati-
tis. From our point of view, it cannot be ultimately ruled
out, that other genetic factors may have contributed to the
development of pancreatitis in the presented cases, as the
researchers did not exclude additional mutations in other
genes including the SPINK1,  PRSS1  and  CFTR  genes.
However, our observation of an individual with a combi-
nation of heterozygous SPINK1 (N34S) and CASR gene
(L173P) mutations, who developed chronic pancreatitis,
may indicate the specific pathogenetic background of CP
within this family.
There is still an ongoing controversy about the relevance
of  SPINK1  mutations in CP although different groups
postulated an association of N34S mutations in patients
with ICP [12,13]. Pfützer et al. reported that
approximately 40 % of their collective of patients with
ICP (n = 57) had a N34S mutation (12 % were
homozygous) [13] while Witt and coworkers detected
N34S mutations in 23 % of their cases (n = 96) in a similar
study [12].
Even though these observations support the importance
of N34S mutations in ICP, it still remains to be
Calcium-sensing receptor gene mutation L173P Figure 2
Calcium-sensing receptor gene mutation L173P The DNA sequence electropherogram of the index patient revealed a 
heterozygous mutation of nucleotide 518T>C. At the bottom, the amino acid sequence corresponding to this DNA region is 
shown. The identified mutation at base 518 results in a T to C transition (518T>C) which leads to a substitution of leucine 173 
by proline in exon 4 (L173P). This corresponds to the extracellular domain of the CaR protein.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/34
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Family tree and clinical parameters of the family with SPINK1 (N34S) and CASR (518T>C) gene mutations Figure 3
Family tree and clinical parameters of the family with SPINK1 (N34S) and CASR (518T>C) gene mutations Two 
family members were diagnosed with chronic pancreatitis and FHH (II:2 and II:4). Mutational analysis of the index patient (36 
years) and three other individuals, respectively, mother (62), unaffected brother (43) and daughter (8) (I:2, II:3, II:4 and III:1) 
showed a heterozygous SPINK1 mutation (N34S). In addition, the index patient and his daughter (II:4, III:1) had a point muta-
tion in exon 4 at position 518 (518T>C) of the CASR gene. As for the individual II:3 in generation I no family member com-
plained about abdominal pain (I:1 deceased in 1971). DNA from the symptomatic brother (39 years) was unavailable for genetic 
testing, but CP and FHH was diagnosed clinically.
I
III
II
123
12 3 4
1
5
*
*
*
chronic pancreatitis
familiar hypocalciuric
hypercalcemia (FHH)
(clinical diagnose)
FHH with heterozygous
CASR (L173P) mutation
heterozygous N34S
SPINK1 mutation
Subject I:2 II:2 II:3 II:4 III:1
chronic pancreatitis Ø X Ø X Ø
age (years) 62 39 43 36 8
N34S heterozygous X unknown X X X
FHH Ø XØXX
CASR mutation (c.518T>C) wild type unknown wild type X X
Plasma Ca 
2+
[mg/dl] normal range
[8.0-10.4] (year)
9.2 (2002) 11.7 (1996) 9.5 (2002) 11.4 (1996)
12.6 (2002) 11.2 (2002)BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/34
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determined whether N34S mutations are causative.
Threadgold et al. postulated that SPINK1 mutations
"rather act as a disease modifying factor but not causing
the disease" [15]. Today their role is further substantiated
as independent groups showed a strong association of
SPINK1 mutations (N34S) in patients with tropical pan-
creatitis [28-30].
Conclusion
Family and clinical history may indicate that the combi-
nation of the N34S SPINK1  and  CASR  gene mutation
induces CP in this kindred. Our observation supports the
hypothesis that SPINK1 mutations rather modify the dis-
ease phenotype than actually cause CP.
This is therefore the first report to show an association
between CASR mutations and SPINK1 related CP. Larger
association studies or animal models are required to elu-
cidate whether the CASR gene plays a more important role
in SPINK1 related CP. The current investigation may thus
represent another part of the mosaique in the complex
model of genetic causes for CP.
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Note
Table 1: Sequences of oligonucleotide primers used for
the PCR of the CASR gene The patient was screened for
published mutations in exons 2–6 (exon 1 is untrans-
lated) of the CASR gene. PCR products were gel-purified
and sequenced on an ABI PRISM 377 DNA sequencer
(Applied Biosystems, Foster, CA) using the listed primers
for PCR and sequencing.
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